SEARCH · Search NASA
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Converts XML file formats to CLI format for 3D printing; combines equivalent polyline segments (laser power, velocity, focus/spot-size) into a single polyline for a given path. Also plots CLI file format with respect to power for a single specified layer, or the entire file, for 3D printed applications.
Highlights: • Authentic squamous cell carcinoma (SqCC) cell lines of the lung are sparse. • HARA lung SqCC cells depend highly on MCL1 for survival in vitro and in vivo. • MCL1-silenced HARA cells decline in number upon docetaxel (DTX) exposure. • High MCL1 mRNA expression is linked with shorter survival in lung SqCC patients. • MCL1 depletion + DTX is highly effective against Detroit 562 pharyngeal SqCC cells. MCL1 is an anti-apoptotic BCL2 family member that is often overexpressed in various malignant tumors. However, few reports have described the role of MCL1 in squamous cell carcinoma (SqCC) derived from airways including the lung. In this study, we examined whether MCL1 could be a novel druggable target for airway-derived SqCC, for which effective molecular targeted drugs are unavailable. We searched the Kaplan–Meier Plotter database and found that high MCL1 mRNA expression was significantly associated with shorter survival in patients with lower airway (lung) or upper airway (head and neck) derived SqCC. We also explored the Expression Atlas database and learned that authentic lung SqCC cell lines expressing both TP63 and KRT5 mRNA were extremely sparse among the publicly available “lung SqCC cell lines”, with an exception being HARA cells. HARA cells were highly dependent on MCL1 for survival, and MCL1-depleted cells were not able to grow, and even declined in number, upon docetaxel (DTX) exposure in vitro and in vivo. Similar in vitro experimental findings, including those in a 3D culture model, were also obtained using Detroit 562 pharyngeal SqCC cells. These findings suggested that combined treatment with MCL1 silencing plus DTX appears highly effective against airway-derived SqCC.
Autophagy drives drug resistance and drug-induced cancer cell cytotoxicity. Targeting the autophagy process could greatly improve chemotherapy outcomes. The discovery of specific inhibitors or activators has been hindered by challenges with reliably measuring autophagy levels in a clinical setting. We investigated drug-induced autophagy in breast cancer cell lines with differing ER/PR/Her2 receptor status by exposing them to known but divergent autophagy inducers each with a unique molecular target, tamoxifen, trastuzumab, bortezomib or rapamycin. Differential gene expression analysis from total RNA extracted during the earliest sign of autophagy flux showed both cell- and drug-specific changes. We analyzed the list of differentially expressed genes to find a common, cell- and drug-agnostic autophagy signature. Twelve mRNAs were significantly modulated by all the drugs and 11 were orthogonally verified with Q-RT-PCR (Klhl24, Hbp1, Crebrf, Ypel2, Fbxo32, Gdf15, Cdc25a, Ddit4, Psat1, Cd22, Ypel3). The drug agnostic mRNA signature was similarly induced by a mitochondrially targeted agent, MitoQ. In-silico analysis on the KM-plotter cancer database showed that the levels of these mRNAs are detectable in human samples and associated with breast cancer prognosis outcomes of Relapse-Free Survival in all patients (RSF), Overall Survival in all patients (OS), and Relapse-Free Survival in ER + Patients (RSF ER + ). High levels of Klhl24, Hbp1, Crebrf, Ypel2, CD22 and Ypel3 were correlated with better outcomes, whereas lower levels of Gdf15, Cdc25a, Ddit4 and Psat1 were associated with better prognosis in breast cancer patients. This gene signature uncovers candidate autophagy biomarkers that could be tested during preclinical and clinical studies to monitor the autophagy process.
With an intense work ethic, and high levels of devotion to their craft, seismologists continue to battle the elements and wrestle with complex logistics in their efforts to field instrumentation over the entire globe. We are fortunate to see data volumes accelerating in size, and quality continuing to improve; for example, universal timing issues can now be considered rare. However, instrument response issues are still common, and can hinder research that seeks to understand amplitudes of seismic wavefields. We are interested in using the accumulations of seismic data to develop models that will predict high frequency (0.2-20 Hz, and higher) signal amplitudes for explosion monitoring purposes over broad areas, which requires large data sets and extensive quality control. To identify response and station health issues, we have collected noise time histories for global seismic data, focusing on measurements near (but not restricted to) midnight to eliminate diurnal variations, and have manually determined time intervals that appear inconsistent with background behavior. We assign descriptive labels, but do not attempt to diagnose causes. We use these intervals to discard data. To date, we have examined 39,260 channels from 11,105 stations, heavily weighted toward IRIS holdings, dates through 2017 (depending on station, roughly the date we started our manual review), bands between 1 and 8 Hz, finding 24,733 anomalous time intervals. The great majority (90%) of these intervals appear to be shifts of constant offset, often bounded by times of known instrument changes, likely the result of poor documentation of response parameters at one of many stages between the field and the plotter. We hope these results can be of use to our colleagues, and would encourage community efforts to diagnose anomalous behavior, and fix poor responses. We also hope these results will support automation efforts, including application of supervised learning techniques.
We had lengthy discussions with Parthian on the interpretation of the original SOW as laid out in the original proposal and on whether or not these tasks were allowable under the rules set by Cal Test Bed. There were also discussions on program limitations on purchasing equipment. We were engaged with vendors identified by Parthian as companies from which we could lease equipment, and in most cases, came to find, that these products were only available for purchase. As a result, we configured translational stages into an x-y plotter arrangement and established computer control over the setup as a step toward building our own system for acquiring data to meet Parthian's requirements. The project reached its scheduled end prior to the start of testing and was allowed to elapse uncompleted.